CYTK Q4 2018 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+52194.4% YoY

Gross Profit

-$14M-148.2% margin

Operating Income

-$21M-228.8% margin

Net Income

-$26M-282.3% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-11.9%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$211M

Total Liabilities

$185M

Stockholders' Equity

$26M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	-$18,000	+52194.4%
Gross Profit	-$14M	-$26M	+47.1%
Operating Income	-$21M	-$37M	+41.3%
Net Income	-$26M	-$40M	+34.6%